Shai Shimony , MD, Dana-Farber Cancer Institute, Boston, MA, shares some key highlights in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) from the EHA 2022 meeting. Dr Shimony first comments on the excitement around the novel Molecular International Prognostic Scoring System (IPSS-M) in MDS, and further discusses clinical trial updates from the meeting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.